Liver cancer associated with good post-transplant outcomes

Patients with liver cancer can become viable candidates for transplantation if their tumors respond to treatment, a new study suggests. This report is in the September issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).

Hepatitis B Genotypes and Mutants May Influence Liver Cancer Risk

Infection with hepatitis B virus (HBV) causes liver cancer in some individuals, but not all strains of the virus are associated with the same degree of risk. If confirmed, the newly reported data could help target chemoprevention strategies in the future.

China's FDA Approves Nexavar For Liver Cancer Treatment

Nexavar Approved For Liver Cancer Treatment in China

Nexavar becomes the latest and newest approved treatment for liver cancer in China. Nexavar is made by Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals and received approval by China's State Food and Drug Administration (SFDA) for liver cancer treatment.

Nexavar Improves Liver Cancer Survival Rates

Nexavar drug is found to improve survival rates in liver cancer patients.

Molecular Discoveries Shed Light On Liver Cancer

Genomics improves our ability to target experimental liver cancer treatments.

Sunitinib May Slow Growth Of Liver Cancer

Treatment with sunitinib slows tumor growth and reduces the risk of metastasis in patients with hepatocellular carcinoma, an aggressive cancer of the liver.

Sunitinib May Slow Growth, Spread Of Liver Cancer

Treatment with sunitinib slows tumor growth and reduces the risk of metastasis in patients with hepatocellular carcinoma, an aggressive cancer of the liver.

FDA Approves Nexavar As First Drug Treatment for Liver Cancer

Nexavar becomes the first FDA-approved drug treatment therapy for patients suffering from liver cancer. Nexavar is made by Bayer Healthcare and the FDA liver cancer treatment node was announced today.

Progen Continues Clinical Program For PI-88 In Liver Cancer

Progen Pharmaceuticals awarded to PI-88 for the prevention of tumour recurrence following curative resection of primary liver cancer and in order to commence the Phase 3 program as rapidly as possible, the Company will no longer continue with the Special Protocol Assessment process.

Molecule Blocks Gene, Sheds Light On Liver Cancer

New research shows how a particular small molecule blocks the activity of a cancer-suppressing gene, allowing liver-cancer cells to grow and spread.

Liver Cancer Symptoms and Treatment